These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 2364440)

  • 1. Effector phenotype and immunologic specificity of T-cell-mediated adoptive therapy for a murine tumor that lacks intrinsic immunogenicity.
    Sakai K; Chang AE; Shu S
    Cell Immunol; 1990 Aug; 129(1):241-55. PubMed ID: 2364440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
    Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
    J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma.
    Sakai K; Chang AE; Shu SY
    Cancer Res; 1990 Jul; 50(14):4371-6. PubMed ID: 2114215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
    Yoshizawa H; Chang AE; Shu S
    J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
    Yoshizawa H; Chang AE; Shu SY
    Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells.
    Shu S; Rosenberg SA
    J Immunol; 1985 Oct; 135(4):2895-903. PubMed ID: 2411817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
    Shu S; Krinock RA; Matsumura T; Sussman JJ; Fox BA; Chang AE; Terman DS
    J Immunol; 1994 Feb; 152(3):1277-88. PubMed ID: 8301131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct immunologic specificity of tumor regression mediated by effector cells isolated from immunized and tumor-bearing mice.
    Chang AE; Perry-Lalley DM; Shu S
    Cell Immunol; 1989 May; 120(2):419-29. PubMed ID: 2785860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. Culture requirements and characterization of immunologic specificity.
    Chou T; Chang AE; Shu SY
    J Immunol; 1988 Apr; 140(7):2453-61. PubMed ID: 2450925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular interactions and the role of interleukin 2 in the expression and induction of immunity against a syngeneic murine sarcoma.
    Chou T; Shu S
    J Immunol; 1987 Sep; 139(6):2103-9. PubMed ID: 2957448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity.
    Shu SY; Chou T; Sakai K
    J Immunol; 1989 Jul; 143(2):740-8. PubMed ID: 2738408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive immunotherapy of newly induced murine sarcomas.
    Shu SY; Rosenberg SA
    Cancer Res; 1985 Apr; 45(4):1657-62. PubMed ID: 3872168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active specific immunotherapy with extracted tumor-specific transplantation antigen, cyclophosphamide, and adoptive transfer of tumor-specific cytotoxic T-cell clones.
    Naito K; Pellis NR; Kahan BD
    Cell Immunol; 1988 Jan; 111(1):216-34. PubMed ID: 3257414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
    Shu SY; Chou T; Rosenberg SA
    J Immunol; 1987 Jul; 139(1):295-304. PubMed ID: 2953816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells.
    Shu S; Chou T; Rosenberg SA
    J Immunol; 1986 May; 136(10):3891-8. PubMed ID: 3486223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-reactivity of anti-CD3/IL-2 activated effector cells derived from lymph nodes draining heterologous clones of a murine tumor.
    Matsumura T; Krinock RA; Chang AE; Shu S
    Cancer Res; 1993 Sep; 53(18):4315-21. PubMed ID: 8364926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors.
    Chou T; Bertera S; Chang AE; Shu S
    J Immunol; 1988 Sep; 141(5):1775-81. PubMed ID: 3261761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice.
    Shu S; Chou T; Rosenberg SA
    Cancer Res; 1987 Mar; 47(5):1354-60. PubMed ID: 3102046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion.
    Wang LX; Chen BG; Plautz GE
    J Immunol; 2002 Sep; 169(6):3314-20. PubMed ID: 12218152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors.
    Plautz GE; Mukai S; Cohen PA; Shu S
    J Immunol; 2000 Oct; 165(7):3656-62. PubMed ID: 11034369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.